ACA vs RYTM Comparison

Arcosa Inc is a manufacturer and producer of infrastructure-related products and solutions in the U.S. It operates in three segments: Construction Products, Engineered Structures, and Transportation Products. Maximum revenue is generated from the Construction Products segment, which produces aggregates, specialty materials, asphalt, and construction support gear. The Engineered Structures segment mainly manufactures and sells steel and concrete structures for infrastructure businesses, including utility structures for electricity transmission and distribution, structural wind towers, traffic and lighting structures, and telecommunication structures; and the Transportation Products segment builds inland barges, fiberglass covers, winches, marine hardware, and other industrial equipment.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.